GREY — Grey Matters Health Share News
0.000.00%
Last trade - 00:00- CA$3.95m
- CA$4.69m
Brief: Algernon Pharmaceuticals Provides Update On Timing Of Topline Results For Phase 2b/3 Covid-19 Trial Of Ifenprodil
Brief: Algernon Pharmaceuticals To Conduct Phase 1 DMT Stroke Program Study With Hammersmith Medicines Research
Brief: Algernon Pharmaceuticals Appoints VP Research & Operations And Chief Medical Officer
Brief: Algernon Provides Update On COVID-19 Phase 2B Final Study Data
Brief: Algernon To Adding Lung Scarring As Additional Endpoint For Phase 2B/3 Covid-19 Study Protocol
Brief: Algernon Pharma Announces Green Light From Data And Safety Monitoring Board To Continue Multinational 2b/3 Human Study Of Ifenprodil For Treatment Of Covid-19
Brief: Algernon Announces 75% Enrollment In Multinational Phase 2B/3 Human Study Of Ifenprodil For Treatment Of Covid-19
Brief: Algernon Announces 50% Enrollment In Multinational 2B/3 Human Study Of Ifenprodil For Treatment Of Covid-19
Brief: Algernon Pharmaceuticals- Announces Enrollment Of 50Th Patient In Multinational 2B/3 Human Study Of Ifenprodil For Treatment Of Covid-19
Brief: Algernon Enrols First U.S. Patient In Phase 2B/3 Human Study Of Ifenprodil For Treatment Of Covid-19
Brief: Algernon Announces First Patient Dosed In Phase 2 Ipf And Chronic Cough Human Trial Of Ifenprodil
Brief: Algernon Receives U.S. FDA Clearance For Multinational Phase 2B/3 Human Study To Evaluate Ifenprodil As A Potential Therapeutic For Covid-19
Brief: Algernon Submits Investigational New Drug Application For Multinational Phase 2B/3 Human Study To Evaluate Ifenprodil For Covid-19
Brief: Algernon Submits Investigational New Drug Application With U.S. FDA For Multinational Phase 2B/3 Human Study To Evaluate Ifenprodil For Covid-19
Brief: Algernon Submits For Ethics Approval In Australia For Study Of Ifenprodil For Covid-19
Brief: Algernon Submits Application To Health Canada For Ifenprodil COVID-19 Phase 2B/3 Multinational Clinical Trial
Brief: Algernon Says Positive Feedback From Health Canada For COVID-19 Treatment Trial
Brief: Algernon Provides Update On Phase 2 Human Testing Of Ifenprodil For COVID-19
Brief: Algernon To Support Planned Phase 2 Trial Of Ifenprodil For Coronavirus